How to buy Vivos Therapeutics stock | $5.55

Vivos Therapeutics, Inc is a medical devices business based in the US. Vivos Therapeutics shares (VVOS) are listed on the NASDAQ and all prices are listed in US Dollars. Vivos Therapeutics employs 110 staff and has a trailing 12-month revenue of around 0.00.

Vivos Therapeutics stock price (NASDAQ: VVOS)

Use our graph to track the performance of VVOS stocks over time.

Vivos Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$5.55
52-week range	$3.00 - $14.41
50-day moving average	$4.80
200-day moving average	$6.51
Wall St. target price	$11.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Vivos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Vivos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Vivos Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vivos Therapeutics price performance over time

Historical closes compared with the close of $5.55 from 2021-05-26

1 week (2021-07-22)	N/A
1 month (2021-07-02)	23.06%
3 months (2021-04-30)	-20.14%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Vivos Therapeutics financials

Revenue TTM	$13.3 million
Gross profit TTM	$10.4 million
Return on assets TTM	-41.41%
Return on equity TTM	-202.54%
Profit margin	-96.68%
Book value	$0.79
Market capitalisation	$71.2 million

TTM: trailing 12 months

Shorting Vivos Therapeutics shares

There are currently 119,726 Vivos Therapeutics shares held short by investors – that's known as Vivos Therapeutics's "short interest". This figure is 193.4% up from 40,811 last month.

There are a few different ways that this level of interest in shorting Vivos Therapeutics shares can be evaluated.

Vivos Therapeutics's "short interest ratio" (SIR)

Vivos Therapeutics's "short interest ratio" (SIR) is the quantity of Vivos Therapeutics shares currently shorted divided by the average quantity of Vivos Therapeutics shares traded daily (recently around 498858.33333333). Vivos Therapeutics's SIR currently stands at 0.24. In other words for every 100,000 Vivos Therapeutics shares traded daily on the market, roughly 240 shares are currently held short.

To gain some more context, you can compare Vivos Therapeutics's short interest ratio against those of similar companies.

• Alexion Pharmaceuticals (ALXN.US): 5.36
• HCA Healthcare (HCA.US): 2.91
• Gilead Sciences (GILD.US): 4.3
• Medtronic (MDT.US): 2.83

However Vivos Therapeutics's short interest can also be evaluated against the total number of Vivos Therapeutics shares, or, against the total number of tradable Vivos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vivos Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Vivos Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0071% of the tradable shares (for every 100,000 tradable Vivos Therapeutics shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vivos Therapeutics.

Find out more about how you can short Vivos Therapeutics stock.

Vivos Therapeutics share dividends

We're not expecting Vivos Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• HCA Healthcare (HCA.US) (0.39% forward annual dividend yield)
• Gilead Sciences (GILD.US) (3.93% forward annual dividend yield)
• Medtronic (MDT.US) (1.78% forward annual dividend yield)

Vivos Therapeutics overview

Vivos Therapeutics, Inc. , a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Frequently asked questions

What percentage of Vivos Therapeutics is owned by insiders or institutions?
Currently 21.774% of Vivos Therapeutics shares are held by insiders and 5.284% by institutions. How many people work for Vivos Therapeutics?
Latest data suggests 110 work at Vivos Therapeutics. When does the fiscal year end for Vivos Therapeutics?
Vivos Therapeutics's fiscal year ends in December. Where is Vivos Therapeutics based?
Vivos Therapeutics's address is: 9137 South Ridgeline Boulevard, Highlands Ranch, CO, United States, 80129